Volume 25, Number 3—March 2019
Dispatch
Neutralizing Antibody against Enterovirus D68 in Children and Adults before 2014 Outbreak, Kansas City, Missouri, USA1
Table
Neutralizing antibody positivity and titers for each enterovirus D68 isolate, by age group, Kansas City, Missouri, 2012–2013
Age group, y | No. | % Neutralizing antibody positive; median (range) neutralizing antibody titer* |
|||
---|---|---|---|---|---|
Fermon | 14-18949 | 14-18952 | 14-18953 | ||
2–5 | 79 | 100; 5.50 (3.17–9.5) | 100; 5.83 (3.5–10.5) | 60; 3.17 (2.5–10.5) | 81; 4.17 (2.5–10.5) |
6–10 | 97 | 100; 6.17 (3.17–10.5) | 100; 7.83 (4.17–10.5) | 89; 7.83 (2.5–10.5) | 83; 6.17 (2.5–10.5) |
11–15 | 91 | 100; 5.83 (3.17–10.5) | 100; 7.83 (3.17–10.5) | 97; 8.50 (2.5–10.5) | 93; 6.50 (2.5–10.5) |
16–50 | 84 | 100; 8.50 (3.83–10.5) | 100; 8.50 (4.83–10.5) | 98; 9.17 (2.5–10.5) | 96; 7.17 (2.5–10.5) |
>50 |
85 |
100; 10.50 (6.5–10.5) |
100; 8.83 (4.83–10.5) |
99; 9.50 (2.5–10.5) |
98; 6.83 (2.5–10.5) |
Total | 436 | 100; 6.83 (2.83–10.5) | 100; 7.83 (3.5–10.5) | 89; 8.34 (2.5–10.5) | 91; 6.50 (2.5–10.5) |
*Antibody titers were measured by using the cell viability kit ATPlite (Perkin Elmer, http://www.perkinelmer.com); the titers shown are the log2 inverse dilution of the lowest antibody concentration with luminescent activity.
1Preliminary results from this study were presented at the Clinical Virology Symposium, May 19–22, 2016, Daytona Beach, Florida, USA.
2These authors contributed equally to this article.